01751-7/asset/f8ffb968-301f-4b4c-9c56-cfb01106603a/main.assets/gr2a_lrg.jpg)
cagrisema cagrilintide semaglutide combination phase 3 results 2024 2025 Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, CagriSema Achieves 22.7% Weight Loss
Description
Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, et al
Only published original and review articles in English were included
10.1387/ijdb.170293jb 43
In order to maintain uniform blood levels and reduce the adverse effect risk, drugs with short half-lives need to be dosed more frequently
